Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hodgkin Disease × Goserelin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 54 Breast Neoplasms 43 Neoplasms 4 Salivary Gland Neoplasms 3 Triple Negative Breast Neoplasms 2 Prostate Adenocarcinoma 2 Recurrence 1 PSA Level Greater Than Two 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphatic Metastasis 1 Inflammatory Breast Neoplasms 1 Hormone-sensitive Metastatic Breast Cancer 1 Hormone Sensitive Prostate Cancer 1 Hodgkin Disease 1 Hereditary Sensory and Autonomic Neuropathies 1 HER2-positive Breast Cancer 1 HER2 Negative Breast Cancer 1 Fallopian Tube Neoplasms 1 Castrate Sensitive Prostate Cancer 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Lobular 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms, Male 1 Anatomic Stage I Breast Cancer AJCC v8 1 Advanced Breast Cancer 1

Interventions

Cyclophosphamide 114 fludarabine phosphate 66 Mycophenolic Acid 61 Etoposide 61 Peripheral Blood Stem Cell Transplantation 58 Tacrolimus 54 Melphalan 48 Filgrastim 48 Busulfan 47 Whole-Body Irradiation 46 Doxorubicin 45 Radiotherapy 42 Brentuximab Vedotin 38 fludarabine 37 Cyclosporine 37 Granulocyte Colony-Stimulating Factor 35 Vinblastine 34 Antilymphocyte Serum 30 Methotrexate 29 Gemcitabine 28 Dacarbazine 28 Rituximab 26 Prednisone 24 Bleomycin 24 Nivolumab 23 Vincristine 22 pembrolizumab 21 Carmustine 21 Cytarabine 20 thymoglobulin 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01014507 2012-06-25

PROFE

University of Cologne

Phase 2 Completed

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡